Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07792993 | Focal Micro-boost Strategy in Patients With Intermediate- to High-risk Prostate Cancer (IR-HR PCa) Undergoing Hypofractionated Radiotherapy(62SPECIAL) | recruiting | — | 82 | Regina Elena Cancer InstituteOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04589468 | Researching the Effect of Exercise on Cancer | recruiting | N/A | 51 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 |
| clinicaltrials |
| NCT04692675 | Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer | recruiting | N/A | 508 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06465966 | UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning | recruiting | N/A | 30 | University of FloridaOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07050433 | COMPASS Study for Metastatic Castration-resistant Prostate Cancer | recruiting | — | 48 | Duke UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07184970 | PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound | recruiting | — | 60 | NYU Langone HealthOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07590934 | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer(PROSPECTOR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 7 | Aug 27, 2026 | clinicaltrials |
| NCT07698535 | Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial | recruiting | Phase 2 | 64 | University of WashingtonOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT02871726 | Transrectal Ultrasound Robot-Assisted Prostate Biopsy | recruiting | N/A | 483 | Johns Hopkins UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06714630 | The PROSECCA Study, Answering New Questions in Prostate Cancer(PROSECCA) | recruiting | — | 15,000 | University of EdinburghOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06960798 | Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) | recruiting | — | 150 | University of OklahomaOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07611110 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)(VECTRA-01) | recruiting | Phase 3 | 670 | AstraZenecaINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT07788625 | ¹⁸F-PSMA-1007 PET-CT-Directed Focal Therapy for MRI-Invisible Prostate Cancer(FOCUS-PSMA) | recruiting | N/A | 60 | The University of Hong KongOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06022822 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06085664 | A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy | recruiting | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07316686 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | recruiting | Phase 1 | 18 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07745361 | Study of Oral MRT-2359 With Apalutamide in Prostate Cancer(MODeFIRe-1) | recruiting | Phase 2 | 25 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT04221542 | Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 479 | AmgenINDUSTRY | 10 | Aug 21, 2026 | clinicaltrials |
| NCT05805371 | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 21 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06369246 | PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer. | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT06844383 | A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide(TALENT) | recruiting | Phase 2 | 126 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07454603 | A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth(PROSTest_STRAT) | recruiting | — | 1,500 | Wren Laboratories LLCINDUSTRY | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04945642 | High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma(HYDRA) | recruiting | N/A | 52 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06785636 | A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC(P300) | recruiting | Phase 1 / Phase 2 | 120 | Pathos AI, Inc.INDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06864533 | Adjuvant Chemotherapy for High Malignant Prostate Cancer(PKUFH-GS5) | recruiting | — | 315 | Peking University First HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06945172 | Comparison of Prostate Cancer-related Quality of Life in Sexually Active Men With Favourable Intermediate-risk Localised Prostate Cancer Treated With Total Prostatectomy or Focal HIFU(QUALIFY) | recruiting | N/A | 102 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07077239 | Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity(MASAMUNE) | recruiting | — | 200 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07227077 | Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial | recruiting | N/A | 50 | Medical College of WisconsinOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07644598 | MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer(MIDAS) | recruiting | Phase 2 | 58 | Georgetown UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | recruiting | Phase 3 | 804 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04775355 | Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer | recruiting | — | 30 | City of Hope Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07109427 | Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System | recruiting | N/A | 40,000 | Washington University School of MedicineOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07231627 | AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions | recruiting | N/A | 50 | University of ArkansasOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07237269 | Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer | recruiting | Phase 2 | 140 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | recruiting | Phase 1 | 60 | Deciphera Pharmaceuticals, LLCINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07052578 | Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration(CONCORD) | recruiting | — | 400 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07455058 | Water Vapor Ablation for Prostate Cancer: Long-Term Registry(VAPOR-LTR) | recruiting | — | 2,500 | Francis Medical Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07594002 | Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy | recruiting | N/A | 40 | University of KentuckyOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03784924 | EDRN Prostate MRI Biomarker Study(P-MRI) | recruiting | — | 950 | University of MichiganOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT06842498 | A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | recruiting | Phase 2 | 75 | Kyntra BioINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06957691 | Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy(Fezo-ADT) | recruiting | Phase 2 | 60 | Shehzad Basaria, M.D.OTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | recruiting | Phase 2 | 60 | City of Hope Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07615101 | Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer. | recruiting | Phase 3 | 365 | Norroy Bioscience Co., LTDINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04812366 | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer(GUNS) | recruiting | Phase 2 | 315 | University of British ColumbiaOTHER | 2 | Aug 14, 2026 | clinicaltrials |
| NCT05043012 | Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study) | recruiting | N/A | 258 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06717711 | Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Robot-assisted Surgical Treatment of Genitourinary Cancers(RCT_LiESWT) | recruiting | Phase 3 | 158 | Regina Elena Cancer InstituteOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06826768 | A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC | recruiting | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2026source: clinicaltrials